FDA reneged on its promise to take a risk-based approach to CDS Software
Mobi Health News
APRIL 11, 2018
About the Author: Bradley Merrill Thompson is a member of the firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory, reimbursement, and clinical trial issues.
113 
Let's personalize your content